Kaitlyn Bader is the senior editor of Dermatology Times® and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.
FDA Approves Historic Roflumilast Foam 0.3% For Seborrheic Dermatitis
December 15th 2023Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.
The Weekly Roundup: November 26-December 1
December 2nd 2023ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.
The Journal Digest: November 20
November 20th 2023This week’s collection of the latest dermatologic studies covers the relationship between melanoma pigmentation and inflammatory cytokines, the negative use of topical nystatin for tinea infections, the association between psoriasis and schizophrenia, and the association between pediatric atopic dermatitis and cardiovascular risk factors.